<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976169</url>
  </required_header>
  <id_info>
    <org_study_id>STU 042013-042</org_study_id>
    <nct_id>NCT01976169</nct_id>
  </id_info>
  <brief_title>Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)</brief_title>
  <official_title>Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Haley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard of care:&#xD;
&#xD;
      Treatment with Trastuzumab&#xD;
&#xD;
      Experimental:&#xD;
&#xD;
      21-Day Cycle of Combination therapy with T-DM1 intravenously on Day 1 and oral PD-0332991 on&#xD;
      Days 5-18&#xD;
&#xD;
      Study Design and Methodology:&#xD;
&#xD;
      This is a phase 1B inter-patient dose escalation study of PD-0332991 in combination with&#xD;
      T-DM1 in patients with recurrent or metastatic HER2-positive breast cancer after prior&#xD;
      trastuzumab or other HER2-directed therapies.&#xD;
&#xD;
      The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes&#xD;
      on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how&#xD;
      well the subject tolerates the treatment.&#xD;
&#xD;
      A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of&#xD;
      PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18&#xD;
      of each 21 day cycle.&#xD;
&#xD;
      Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral)&#xD;
      Cohort 3 : PD-0332991 - 200 mg daily (oral)&#xD;
&#xD;
      The 3+3 design entails that if one patient out of the first three patients has a DLT, up to&#xD;
      three additional patients will be entered at that dose level&#xD;
&#xD;
      Treatment cycles will continue until disease progression or withdrawal from study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1B inter-patient dose escalation study of PD-0332991 in combination with&#xD;
      T--DM1 in patients with recurrent or metastatic HER2-positive breast cancer after prior&#xD;
      trastuzumab or other HER2-directed therapies. A standard 3+3 trial design will be used for&#xD;
      PD-0332991 dose escalation cohorts. The 3+3 design entails that if one patient out of the&#xD;
      first three patients has a dose-limiting toxicity (DLT), three additional patients will be&#xD;
      entered at that dose level. The PD-0332991 dose levels will start at 100 mg po daily; the&#xD;
      second cohort will receive 150mg po daily; the third cohort 200mg po daily. Patients receive&#xD;
      PD-0332991 on days 5-18 of each 21 day cycle. T-DM1 will be given intravenously at 3.6 mg/kg&#xD;
      on day 1 of each 21 day cycle.&#xD;
&#xD;
      Toxicity will be assessed using the Common Terminology Criteria of Adverse Events (CTCAE)&#xD;
      version 4.0 grading scale. Dose- limiting toxicity-DLT is defined as any drug-related grade 3&#xD;
      non-hematologic toxicity or grade 4 hematologic toxicity lasting &gt;28 days after the last day&#xD;
      of therapy. If two patients experience drug-related DLT, the maximal tolerated dose (MTD) for&#xD;
      the combination in HER2-positive breast cancer patients has been exceeded, enrollment to that&#xD;
      dose will stop, and the next lower dose will be designated the MTD. An additional 15 patients&#xD;
      will be treated at the MTD or the maximal 200mg po daily PD-0332991 dose in combination with&#xD;
      T-DM1 to confirm safety. Treatment cycles will continue until disease progression or&#xD;
      withdrawal from study.&#xD;
&#xD;
      Study End-points:&#xD;
&#xD;
        1. To evaluate and assess Dose Limiting Toxicities (DLT).&#xD;
&#xD;
        2. To determine the toxicity profile.&#xD;
&#xD;
        3. To determine the clinical response rate.&#xD;
&#xD;
        4. To determine the duration of response.&#xD;
&#xD;
        5. To evaluate baseline HER2 positivity biomarkers by analyzing pretreatment tumor Ki67,&#xD;
           phospho-RB, cleaved caspase 3, phospho-histone H3, cycline E, MCM7, HER2, p27Kip1.&#xD;
&#xD;
        6. To evaluate post-treatment Ki67, phospho-RB, cleaved caspase 3, phospho-histone H3,&#xD;
           cyclin E, MCM7, HER2, p27Kip1, Rb, p16ink4c, CDK4, CDK6 in order to establish biomarker&#xD;
           response to treatment.&#xD;
&#xD;
        7. To evaluate pharmacokinetic (PK) parameters for PD-0332991 and T-DM1 including Cmax,&#xD;
           AUC, t1/2&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 24, 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>42 days at the end of Cycle 2</time_frame>
    <description>A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.&#xD;
Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>42 days at the end of Cycle 2</time_frame>
    <description>The 3+3 design entails that if one patient out of the first three patients has a DLT, up to three additional patients will be entered at that dose level</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PD-0332991 and T-DM1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.&#xD;
A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.&#xD;
Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-0332991 and T-DM1</intervention_name>
    <description>The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.&#xD;
A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.&#xD;
Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)</description>
    <arm_group_label>PD-0332991 and T-DM1</arm_group_label>
    <other_name>KADCYLA=T-DM1</other_name>
    <other_name>Palbociclib=PD-0332991</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.All subjects must be informed about the study and have signed a current IRB&#xD;
             (Institutional Review Board) approved informed consent.&#xD;
&#xD;
             2. All subjects must have recurrent or metastatic HER2-positive breast cancer.&#xD;
             diagnosed by biopsy.&#xD;
&#xD;
             3. All subjects must have previously received trastuzumab or other HER2 targeted&#xD;
             therapies.&#xD;
&#xD;
             4.Tumor must be HER2-positive and RB-proficient. RB (Retinoblastoma&#xD;
             protein)-proficiency is determined by tumor biopsy demonstrating RB normal and p16in4a&#xD;
             low by immunohistochemistry. RB proficiency means that there is an intact RB pathway&#xD;
             indicative of responsiveness to PD-0332991. RB staining is scored on an absent (no&#xD;
             nuclear staining), weak (nuclear staining less than observed in endothelial cells and&#xD;
             stromal cells surrounding the tumor), positive (nuclear staining at or above&#xD;
             surrounding tissue) (0, 0.5, 1 respectively). P16ink4a is a routine clinical stain&#xD;
             that is scored using absent, weak, positive, strong (0,1,2,3 respectively). Tumors&#xD;
             will be scored using [p16]/[RB], where a score of less than 3 is required for&#xD;
             inclusion. RB loss is expected to occur in less than 15% of cases.&#xD;
&#xD;
             5. Subjects must have a performance status of â‰¤ 2 on the ECOG (Eastern Cooperative&#xD;
             Oncology Group)Performance scale.&#xD;
&#xD;
             6. Subjects must have bilirubin &lt;1.5 mg/dl, transaminases &lt;2.5x upper limit of normal,&#xD;
             albumin &gt;3gm/dl, creatinine &lt;1.3mg/dl, adequate cardiac reserve (EF&gt;50%), ANC&#xD;
             (Absolute neutrophil count) &gt;1,000/mcL (microliter), and Platelets &gt;100,000/mcL.&#xD;
&#xD;
             7. Must be willing to be treated at the University of Texas Southwestern Hospital,&#xD;
             University of Pennsylvania and affiliated clinics.&#xD;
&#xD;
             8. Subjects must be willing to use an approved form of birth control while on this&#xD;
             study and for 90 days after completion.&#xD;
&#xD;
             9. Age &gt; 18 years. 10. Subject must be able to swallow capsules and have no surgical&#xD;
             or anatomic condition that will preclude the subject from swallowing and absorbing&#xD;
             oral medications on an ongoing basis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Chemotherapy, radiotherapy or hormonal therapy within 3 weeks ( 6 weeks for&#xD;
             nitrosoureas, mitomycin C or bevacizumab), or who have not recovered from the adverse&#xD;
             events to &lt; grade 2 due to previous agents administered more than 4 weeks prior to&#xD;
             Study Day 1.&#xD;
&#xD;
             2. Subjects less than 4 weeks post major surgery. 3. Known active CNS metastases or&#xD;
             carcinomatous meningitis. Subjects with CNS (Central Nervous System) metastases&#xD;
             including brain metastases who have completed a course of radiotherapy are eligible&#xD;
             for the study provided they are clinically stable. However, oral corticosteroids for&#xD;
             control of CNS symptoms are not allowed.&#xD;
&#xD;
             4. Known documented or suspected hypersensitivity to the components of the study&#xD;
             drug(s) or analogs.&#xD;
&#xD;
             5. Uncontrolled systemic illness, including but not limited to ongoing or active&#xD;
             infection.&#xD;
&#xD;
             6. Symptomatic congestive heart failure, unstable angina pectoris, stroke or&#xD;
             myocardial infarction within 3 months.&#xD;
&#xD;
             7. Baseline neuropathy &gt;grade 1. 8. Known positive for human immunodeficiency virus&#xD;
             (HIV). Baseline HIV screening is not required.&#xD;
&#xD;
             9. Pregnant or breast-feeding subjects. 10. Subjects who are unable or unwilling to&#xD;
             abide by the study protocol or to cooperate fully with the investigator or designee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Haley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal Medicine Hematology Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2013</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Barbara Haley</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

